Dicot Appoints Mangold as Liquidity Provider
September 5, 2019, Uppsala, Sweden - Dicot AB (publ) ("Dicot" or the "Company") has appointed Mangold Fondkommission as liquidity provider for the Company"s shares listed on Spotlight Stock Market.
A liquidity provider's aim is to improve the liquidity of a share and reduce the spread between the bidding and asking price. Mangold Fondkommission's assignment commences on September 6, 2019.
Mangold will fulfill its assignment as liquidity provider to ensure the possibility of trading in Dicot's share every day by continuously placing trading records on each purchase and sales page in the order book. A liquidity provider aims to create a more accurate pricing of a company"s share, which in turn gives a more accurate valuation of the company and allows for an improved trading volume in the share.
For further information, please contact:
Julie Silber, CFO and Director of Investor Relations, Dicot
Tel: +46 79 348 62 77
E-mail: [email protected]
www.dicot.se
About Dicot AB
Dicot is a pharmaceutical company focused on drug discovery and the development of novel lifestyle drugs to enrich patients" lives. The Company develops and manufactures medicines for the treatment of erectile dysfunction and premature ejaculation. The company"s lead product, Libiguin™, for the treatment of sexual dysfunctions, is in a stage of pre-clinical development. Dicot is listed on the Spotlight Stock Market and has approximately 700 shareholders. For more information see www.dicot.se.
Filer
Om Dicot Pharma
Dicot utvecklar ett modernt potensläkemedel som ska behandla erektionssvikt och för tidig utlösning bättre än befintliga preparat.
Handelsinformation
IR-Kontakt
